Avanos Medical (AVNS) EBIT (2013 - 2026)

Avanos Medical has disclosed EBIT across 14 years of filings, most recently posting $8.9 million for Q1 2026.

• EBIT for Q1 2026 came in at $8.9 million, down 13.59% year-over-year; the trailing twelve-month figure through Mar 2026 was -$63.0 million (up 83.84% YoY), and the FY2025 annual result was -$61.6 million, up 84.45% from the prior year.
• EBIT came in at $8.9 million for Q1 2026 at Avanos Medical, up from $2.5 million in the prior quarter.
• In the past five years, EBIT ranged from a high of $16.6 million in Q4 2022 to a low of -$418.5 million in Q4 2024.
• The 5-year median for EBIT is $6.3 million (2024), against an average of -$23.3 million.
• Peak annual rise in EBIT reached 900.0% in 2024, while the deepest fall reached 3836.61% in 2024.
• Avanos Medical's EBIT stood at $16.6 million in 2022, then tumbled by 32.53% to $11.2 million in 2023, then sank by 3836.61% to -$418.5 million in 2024, then jumped by 100.6% to $2.5 million in 2025, then jumped by 256.0% to $8.9 million in 2026.
• The last three EBIT figures came in at $8.9 million (Q1 2026), $2.5 million (Q4 2025), and $100000.0 (Q3 2025), per Business Quant data.